Opus Genetics Secures Strategic \$155 Million Non-Dilutive Financing from Oberland Capital
Key Points for Investors
- Non-Dilutive Financing Agreement: Opus Genetics, Inc. has entered into a strategic financing agreement with Oberland Capital, providing access to up to \$155 million in non-dilutive funding, including an immediate \$35 million upfront payment and a \$5 million equity investment.
- Extended Cash Runway: Current cash resources, now approximately \$100 million, combined with this new facility, extend Opus’ cash runway into 2029. This covers the expected completion of pivotal studies for OPGx-LCA5 and OPGx-BEST1, potential product approvals, and the opportunity to receive priority review vouchers.
- Accelerated Pipeline Development: The financing will be used to accelerate the development of earlier-stage gene therapy programs, with three additional programs (OPGx-RDH12, OPGx-MERTK, and OPGx-RHO) entering clinical testing over the next year.
- Key Clinical Milestones:
- Three-month topline results from Cohort 1 of the Phase 1/2 trial for OPGx-BEST1 are on track for mid-2026.
- OPGx-RDH12 expected to enter U.S. clinics in Q4 2026.
- OPGx-MERTK to initiate clinical trials by end of 2026, with a focus on the MENA region.
- OPGx-RHO scheduled to enter the clinic in 2027.
- Favorable Financing Terms: The note facility has an initial \$35 million tranche, a second \$35 million available at Opus’ option within 12 months, and further tranches tied to milestones and mutual agreement. Notes mature in seven years, with a six-year interest-only period and a low initial cash interest rate (~4.1%). Up to 10% of each note’s principal is convertible into common stock at \$6.72 per share.
- \$5 Million Equity Investment: Oberland Capital will make a \$5 million equity investment in Opus Genetics at \$4.48 per share, based on the 30-day VWAP, with 1.1 million shares to be issued.
- Leverage of Non-core Assets: The financing facility allows Opus to leverage its non-core commercial phentolamine asset, providing further financial flexibility to focus on its gene therapy platform.
- Strategic Partnerships: Several pipeline programs are supported by strategic partnerships, including with the RDH12 Alliance and the Department of Health – Abu Dhabi.
- Potential Value Drivers: The successful development and approval of pipeline programs, as well as the receipt of priority review vouchers, represent key potential catalysts for shareholder value.
Details of the Financing Agreement
Under the agreement, Opus Genetics will issue an initial \$35 million in notes at closing (expected April 20, 2026). A further \$35 million may be accessed within 12 months, and an additional \$35 million upon achievement of regulatory milestones related to the potential approval of OPGx-LCA5. Up to \$50 million in further tranches may be accessed by mutual agreement through December 2027.
The notes mature seven years from issuance, with a six-year interest-only period and a repayment of 50% of the outstanding notes on the sixth anniversary. The interest rate is floating, subject to a floor and cap, and 50% of the interest for the first eight quarters will be paid-in-kind and added to the principal. Up to 10% of the principal is convertible to stock at \$6.72 per share.
Alongside the note purchase, Oberland Capital will acquire 1.1 million shares of Opus Genetics common stock in a private placement for \$5 million, at a price of \$4.48 per share. The closing of this equity investment is expected to occur concurrently with the closing of the initial note issuance.
Clinical Pipeline and Milestones
- OPGx-LCA5 and OPGx-BEST1: Pivotal studies for these lead programs are expected to be completed with the current funding. OPGx-BEST1’s Phase 1/2 topline results are anticipated mid-2026.
- OPGx-RDH12: Targeting LCA caused by RDH12 mutations, this program is expected to enter U.S. clinical trials in Q4 2026. It addresses an estimated 2,500 U.S. patients and 30,900 globally. It is partially funded by the RDH12 Alliance.
- OPGx-MERTK: To enter the clinic by end of 2026, in partnership with the Department of Health – Abu Dhabi, focusing on a large patient population in the MENA region (14,300), as well as 2,600 in the U.S. and 21,960 globally.
- OPGx-RHO: A program addressing autosomal dominant retinitis pigmentosa; trials are planned for 2027, targeting 8,800 U.S. patients and 30,000 globally. The approach involves knockdown of mutant rhodopsin and replacement with wild-type protein.
- Other Programs: Opus is developing additional gene therapies for CNGB1, RPE65, and NMNAT1, as well as a small-molecule therapy (Phentolamine Ophthalmic Solution 0.75%) with expanded indications in presbyopia and post-keratorefractive surgery.
Shareholder Impact and Price-Sensitive Information
The addition of up to \$155 million in non-dilutive capital significantly strengthens Opus’ balance sheet, extending its runway into 2029 and fully funding several key clinical and pre-launch initiatives. The structure of the financing avoids substantial dilution for existing shareholders and provides financial flexibility to accelerate development across a broad pipeline. The potential for up to 10% of the note principal to convert into common stock at a premium price is also noteworthy for shareholders monitoring dilution risk.
Key upcoming milestones—including pivotal data readouts, potential regulatory approvals, and the possibility of earning priority review vouchers—represent significant catalysts that could materially impact the share price. The strategic partnership with Oberland Capital, which brings both capital and industry validation, further enhances Opus Genetics’ position and could attract increased investor attention.
Furthermore, the company’s ability to leverage its non-core commercial asset (phentolamine) and its ongoing expansion of the pipeline through partnerships and alliances could drive additional shareholder value.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The company’s pipeline includes seven AAV-based programs, with key assets in LCA5 and BEST1, and further candidates in RHO, CNGB1, RPE65, NMNAT1, and MERTK. Opus is also advancing a small-molecule therapy for ophthalmic indications.
Disclaimer
This article contains forward-looking statements based on current expectations, subject to risks and uncertainties that could cause actual results to differ materially. Investors are advised to review the company’s filings with the SEC, including risk factors, and not to rely solely on this summary for investment decisions. The information herein does not constitute investment advice.
